Gemcitabine + cisplatin (advanced biliary tract cancer, 1L — ABC-02)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-GEMCITABINE DRUG-CISPLATIN |
|---|
| ID | REG-GEMCITABINE-CISPLATIN-CHOLANGIO |
|---|---|
| Type | Regimen |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-CNS-2025 |
Notes
STUB scaffold. Dosing summary only.
Used By
Indication
IND-CHOLANGIO-ADVANCED-GEM-CIS- IND-CHOLANGIO-ADVANCED-GEM-CIS